Identifying new targets for treating metastatic colorectal cancer
Official title: Targeting the evolving immunopeptidome of metastatic colorectal cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11035804 · Data updated 2026-11-12
This study is looking for special markers in advanced colorectal cancer that could help create better treatments using CAR T cell therapy, aiming to find targets that are unique to cancer cells and not found in healthy tissues, so patients can have more effective options for their care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $154,642 |
| NIH project number | 1K99CA297011-01 |
| Project ID | NIH-11035804 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with metastatic colorectal cancer who are HLA-A*02:01 positive.
✕Less likely to help
Patients with early-stage colorectal cancer or those who do not express the HLA-A*02:01 allele may not benefit from this research.
What this research studies
This research investigates the immunopeptidome of metastatic colorectal cancer (mCRC) to find specific targets for chimeric antigen receptor (CAR) T cell therapies. By analyzing peptides presented by human leukocyte antigen (HLA) class I molecules, the study aims to uncover cancer-specific antigens that could improve treatment outcomes. The researchers will utilize patient-derived organoids to model the disease and identify unique peptide targets that are prevalent in cancer cells but absent in healthy tissues. This approach seeks to enhance the effectiveness of immunotherapy for patients with advanced colorectal cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for patients with metastatic colorectal cancer.
How similar studies have gone: Other research has shown promise in targeting the immunopeptidome in various cancers, suggesting that this approach could be effective for colorectal cancer as well.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lee, Jaeyop — Sloan-Kettering Inst Can Research
- Study coordinator: Lee, Jaeyop
Related research
Other NIH-funded projects on the same topics.
-
Population-based view of patient-reported outcomes in adults with metastatic colorectal cancer
This grant funds a long-term study to understand experiences and quality of life for adults living with metastatic colorectal cancer.
-
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer
A new nanoscale therapy called CF10 is being developed to deliver a chemotherapy drug more directly to metastatic colorectal cancer, aiming for better tumor targeting and fewer side effects.
-
How metastatic colorectal cancer weakens muscles and bones
This research looks at how metastatic colorectal cancer and a hormone called FGF21 cause muscle and bone wasting in people with advanced colorectal cancer.
-
Nanoscale polymers delivering patient-specific cancer vaccines for metastatic colorectal cancer
A new therapy uses tiny, designer particles to carry patient-specific cancer antigens to tumors in people with advanced colorectal cancer.
-
Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer
Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.
-
Symptoms and quality of life in adults living with metastatic colorectal cancer
Researchers will follow adults with metastatic colorectal cancer over time to learn what symptoms and quality-of-life issues they experience during treatment and survivorship.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.